# Licaminlimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/licaminlimab

> The next catalyst for licaminlimab, sponsored by Oculis Holding AG (OCS), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | licaminlimab |
| Codes | OCS-02 |
| Sponsor | Oculis Holding AG (OCS) https://sec-api.dev/companies/ocs/catalysts |
| Indications | signs in moderate to severe ded, signs and symptoms of moderate to severe ded, [Dry Eye Disease (DED)](https://sec-api.dev/indications/dry-eye-disease-ded) |
| Modality | antibody |
| FDA designations | breakthrough |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: signs and symptoms of moderate to severe DED.
- First seen 2025-03-11, last confirmed 2026-04-21.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab as a treatment for moderate-to-severe DED in which Licaminlimab was well tolerated, similar to vehicle." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "The Phase 2b RELIEF trial evaluating the potential of Licaminlimab, our innovative anti-TNFα biologic eye drop, for the treatment of signs in moderate to severe DED, was completed with positive topline results announced in June 2024." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab as a treatment for moderate-to-severe DED." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- SEC Form 10-K (accession 0001193125-26-091446): "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab as a treatment for moderate-to-severe DED in which Licaminlimab was well tolerated, similar to vehicle." https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/ocs-20251231.htm
- SEC Form 10-K (accession 0001193125-26-091446): "The Phase 2b RELIEF trial evaluating the potential of Licaminlimab, our innovative anti-TNFα biologic eye drop, for the treatment of signs in moderate to severe DED, was completed with positive topline results announced in June 2024." https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/ocs-20251231.htm
- SEC Form 10-K (accession 0001193125-26-091446): "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab as a treatment for moderate-to-severe DED." https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/ocs-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-068021): "Based on results achieved in three Phase 2 clinical trials, we advanced Licaminlimab (OCS-02) into a Phase 2b RELIEF clinical trial to assess its clinical benefit in treating DED, for which we announced positive topline results in June 2024." https://www.sec.gov/Archives/edgar/data/1953530/000095017025068021/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-068021): "Our clinical portfolio is made up of (i) OCS-01, currently in two ongoing Phase 3 clinical trials for DME and in NDA preparation for inflammation and pain following ocular surgery; (ii) Privosegtor (OCS-05), a novel neuroprotective agent with potential expansion into neurodegenerative diseases in ophthalmology and neurology, which we are initially developing as a potential treatment for acute optic neuritis; and (iii) Licaminlimab (OCS-02), for which we announced positive topline results from our Phase 2b RELIEF trial in June 2024 and for which we consulted with the FDA in the first quarter of 2025 and confirmed a development path forward with a precision medicine approach." https://www.sec.gov/Archives/edgar/data/1953530/000095017025068021/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-068021): "The Phase 2b RELIEF trial evaluating the potential of Licaminlimab (OCS-02), our innovative anti-TNFα biologic eye drop, for the treatment of signs and symptoms of moderate to severe DED, was completed with positive topline results announced in June 2024." https://www.sec.gov/Archives/edgar/data/1953530/000095017025068021/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-068021): "In June 2024, we announced positive topline results from the Phase 2b RELIEF study evaluating Licaminlimab (OCS-02) as a treatment for moderate-to-severe DED." https://www.sec.gov/Archives/edgar/data/1953530/000095017025068021/ocs-ex99_4.htm
- SEC Form 10-K (accession 0000950170-25-037224): "Based on results achieved in three Phase 2 clinical trials, we advanced Licaminlimab (OCS-02) into a Phase 2b RELIEF clinical trial to assess its clinical benefit in treating DED, for which we announced positive topline results in June 2024." https://www.sec.gov/Archives/edgar/data/1953530/000095017025037224/ocs-20241231.htm
- SEC Form 10-K (accession 0000950170-25-037224): "Our clinical portfolio is made up of (i) OCS-01, currently in two ongoing Phase 3 clinical trials for DME and in NDA preparation for inflammation and pain following ocular surgery; (ii) Privosegtor (OCS-05), a novel neuroprotective agent with potential expansion into neurodegenerative diseases in ophthalmology and neurology, which we are initially developing as a potential treatment for acute optic neuritis; and (iii) Licaminlimab (OCS-02), for which we announced positive topline results from our Phase 2b RELIEF trial in June 2024 and for which we consulted with the FDA in the first quarter of 2025 and confirmed a development path forward with a precision medicine approach." https://www.sec.gov/Archives/edgar/data/1953530/000095017025037224/ocs-20241231.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2/3.
- First seen 2025-08-21, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-274212): "We plan to initiate PREDICT-1, a registrational trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1953530/000119312525274212/ocs-ex99_2.htm
- SEC prospectus (424B) (accession 0001193125-25-260967): "We plan to initiate PREDICT-1, a registrational trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1953530/000119312525260967/d95621d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-260991): "We plan to initiate PREDICT-1, a registrational trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1953530/000119312525260991/d93746d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-185344): "We plan to initiate a first Phase 2/3 registrational trial of Licaminlimab (OCS-02) in DED in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1953530/000119312525185344/ocs-ex99_2.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Dry Eye Disease (DED).
- First seen 2026-03-03, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "After a successful FDA meeting in the first quarter of 2025, we initiated the PREDICT-1 registrational Phase 2/3 trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025 for which topline results are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-216741): "After a successful FDA meeting in the first quarter of 2025, we initiated the PREDICT-1 registrational Phase 2/3 trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025 for which topline results are expected around the end of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/ocs-ex99_2.htm
- SEC Form 10-K (accession 0001193125-26-091446): "After a successful FDA meeting in the first quarter of 2025, we initiated the PREDICT-1 registrational Phase 2/3 trial with a genotype-based approach to investigate Licaminlimab in DED in the fourth quarter of 2025 for which topline results are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/ocs-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "The intent is to drive a precision medicine approach in DED, for the very first time, and topline results from the PREDICT-1 trial are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-166790): "Topline results from this trial are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/ocs-ex99_4.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088209): "Topline results from PREDICT-1 are expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526088209/ocs-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-445380): "Topline results are anticipated around year-end 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526445380/ocs-ex99_3.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-445380): "PREDICT-1 topline results are expected around year-end; if positive, they would position Licaminlimab to potentially become the first precision medicine in ophthalmology, specifically targeting TNFR1-mediated dry eye disease." https://www.sec.gov/Archives/edgar/data/1953530/000119312526445380/ocs-ex99_3.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338054): "With Licaminlimab PREDICT-1 trial site activations complete and a third of patients enrolled, we expect to report topline results around year-end." https://www.sec.gov/Archives/edgar/data/1953530/000119312526338054/ocs-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338054): "In parallel, with Licaminlimab PREDICT-1 genotype-based trial planned site activations complete and over 45% of patients enrolled, we expect to report topline results around year-end." https://www.sec.gov/Archives/edgar/data/1953530/000119312526338054/ocs-ex99_3.htm
- SEC Form 10-K (accession 0001193125-26-091446): "The intent is to drive a precision medicine approach in DED, for the very first time, and topline results from the PREDICT-1 trial are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/ocs-20251231.htm
- ClinicalTrials.gov: "NCT07548632 (A Clinical Study Evaluating Licaminlimab for Dry Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Oculis." https://clinicaltrials.gov/study/NCT07548632

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Dry Eye Disease (DED).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07548632 (A Clinical Study Evaluating Licaminlimab for Dry Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Oculis." https://clinicaltrials.gov/study/NCT07548632

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/licaminlimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Licaminlimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/licaminlimab

```bibtex
@misc{secapidev_pdufa_licaminlimab_20261116,
  title        = {Licaminlimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/licaminlimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_licaminlimab_20261116","title":"Licaminlimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/licaminlimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
